Current Report Filing (8-k)
December 06 2022 - 7:34AM
Edgar (US Regulatory)
0000827871
false
0000827871
2022-12-06
2022-12-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): December 6, 2022
Eagle Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
001-36306 |
20-8179278 |
(State
or other jurisdiction of |
(Commission File Number) |
(IRS Employer Identification No.) |
incorporation) |
|
|
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 326-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name
of each exchange on which registered |
Common Stock (par value $0.001 per share) |
|
EGRX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 | Regulation FD Disclosure. |
On December 6, 2022, Eagle Pharmaceuticals,
Inc., or the Company, released an investor presentation relating to the Company’s hospital-based products and product candidates,
including BARHEMSYS, BYFAVO, Landiolol, and CAL02 and Enalare Therapeutics Inc.’s ENA-001. The Company will refer to the presentation
during its previously announced Investor Day taking place on December 6, 2022, at 8:00am ET.
A copy of the above-referenced presentation is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant
to Item 7.01 of this current report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall
not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or
the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing,
except as shall be expressly set forth by specific reference in such filing. The furnishing of the information in this Current Report
on Form 8-K is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current
Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with
respect to any security of the Company.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 6, 2022 |
EAGLE PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Scott Tarriff |
|
|
Scott Tarriff |
|
|
Chief Executive Officer |
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024